StreetInsider.com News Articles

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Thu, 16 Jul 2026 07:00:00 -0400

Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes), announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which is expected to conclude

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Thu, 16 Jul 2026 07:00:00 -0400

Telo Genomics files patent for liquid biopsy MRD use in myeloma

Thu, 09 Jul 2026 07:02:18 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has filed a U.S. provisional patent application to protect a new TeloView biomarker algorithm designed for use with liquid biopsy samples in the management of multiple myeloma patients, including those with minimal residual disease (MRD).

The application seeks to cover an algorithm that can predict relapse risk in multiple myeloma patients, as well as a workflow to isolate circulating cancer cells from peripheral blood samples in the MRD setting.

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView platform," said John Farlinger, Telo's CEO.

Currently available MRD technologies primarily

Telo Genomics files patent for liquid biopsy MRD use in myeloma

Thu, 09 Jul 2026 07:02:18 -0400

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView platform," said John Farlinger, Telo's CEO.

Currently available MRD technologies primarily

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Thu, 09 Jul 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM").

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView® platform," said John Farlinger, Telo's CEO. "As MRD becomes increasingly important in multiple myeloma

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Thu, 09 Jul 2026 07:00:00 -0400

Telo Genomics Announces Termination of Investor Relations Agreement

Fri, 26 Jun 2026 20:58:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties that this was a transitory role for Sheridan and was not intended to be long term. The Company wishes Sheridan well with its future endeavours.

About Telo Genomics

Telo

Telo Genomics Announces Termination of Investor Relations Agreement

Fri, 26 Jun 2026 20:58:00 -0400

About Telo Genomics

Telo

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Form D Telo Genomics Corp.

Fri, 24 Apr 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260424/26366764.html

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Tue, 14 Apr 2026 07:00:00 -0400

Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes) today announced the launch of a new retrospective clinical study in collaboration with leading hematologists at the National and Kapodistrian University of Athens, Dr.

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Tue, 14 Apr 2026 07:00:00 -0400

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Tue, 31 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered into a management consulting agreement. Mr. Farlinger is a seasoned public markets, venture and private equity-backed executive and entrepreneur, bringing more than 30 years of experience in operations, technology and

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Tue, 31 Mar 2026 07:00:00 -0400

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mon, 09 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news releases dated January 19, 2026, February 18, 2026, and February 27, 2026) by issuing Debentures for gross proceeds of $545,000 (the "Second Tranche"), for aggregate gross proceeds from the

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mon, 09 Mar 2026 07:00:00 -0400

Telo Genomics increases private placement to $1.6 million

Fri, 27 Feb 2026 15:34:12 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced it has increased the size of its previously announced private placement of convertible debentures from $1,200,000 to $1,600,000.

The debentures will carry a 15% annual interest rate, compounded quarterly, and mature on December 15, 2026. Holders can convert the principal amount into common shares at $0.05 per share before maturity. The company cannot prepay the debentures prior to the maturity date.

For every $100,000 of convertible debentures issued, the company will issue 2 million detachable warrants. Each warrant allows the purchase of one common share at $0.08 per share for 12 months from the

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Fri, 27 Feb 2026 15:32:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from up to $1,200,000 to up to $1,600,000 (the "Upsized Offering").

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date"). The principal

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Fri, 27 Feb 2026 15:32:00 -0400

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date"). The principal

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Wed, 18 Feb 2026 07:00:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news release dated January 19, 2026) by issuing Debentures for gross proceeds

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Wed, 18 Feb 2026 07:00:00 -0400

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Telo Genomics appoints John Price as chief financial officer

Thu, 29 Jan 2026 08:02:11 -0400

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced the appointment of John Price as chief financial officer, effective January 30, 2026, according to a press release statement.

Price brings over 30 years of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His background includes executive positions at publicly traded companies such as Assure Holdings, National Beverage, Alliance MMA, and MusclePharm.

Price also held accounting and finance roles at technology companies in Silicon Valley, including Opera Software, GCT Semiconductor and Tessera Technologies. He began his career with seven years at Ernst & Young and holds a Bachelor of Science

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Thu, 29 Jan 2026 08:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately.

Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. Mr. Price's prior experience includes executive positions in several public companies including Assure

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Thu, 29 Jan 2026 08:00:00 -0400